Maximizing the impact of antimicrobial stewardship: The role of diagnostics, national and international efforts

Current Opinion in Infectious Diseases

Volumn 26, Issue 4, 2013, Pages 352-358

  O'Brien, Deirdre J ^a   Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

antimicrobial stewardship; biomarkers; molecular diagnostic techniques

Indexed keywords

ANTIINFECTIVE AGENT; PHARMACOLOGICAL BIOMARKER; PNEUMOCOCCUS VACCINE; PROADRENOMEDULLIN; PROCALCITONIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ANTIBIOTIC RESISTANCE; CLINICAL DECISION MAKING; DRUG DESIGN; HEALTH EDUCATION; INFECTION PREVENTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; PROTEIN EXPRESSION; REVIEW; SEASONAL INFLUENZA; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTICEMIA; SPECIES IDENTIFICATION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84879870203     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283631046     Document Type: Review

References (50)

1. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-177. (Pubitemid 46084814)
2. Allerberger F, Mittermayer H. Antimicrobial stewardship. Clin Microbiol Infect 2008; 14:197-199. (Pubitemid 351201009)
3. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society, (PIDS). Infect Control Hosp Epidemiol 2012; 33:322-327.
4. McNulty CA, Cookson BD, Lewis MA. Education of healthcare professionals and the public. J Antimicrob Chemother 2012; 67 (Suppl 1):i11-i18.
5. Beardsley JR, Williamson JC, Johnson JW, et al. Show me the money: longterm financial impact of an antimicrobial stewardship program. Infect Control Hosp Epidemiol 2012; 33:398-400.
6. Standiford HC, Chan S, Tripoli M, et al. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012; 33:338-345.
7. Dancer SJ, Kirkpatrick P, CorcoranDS, et al.Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended- spectrum beta-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013; 41:137-142.
8. Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817-830.
9. Howard P, Pulcini C. Development of a worldwide antimicrobial stewardship survey. Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 31 March-3 April 2012, London, UK; 2012. Poster 1059
10. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. (Pubitemid 43810035)
11. Seng P, Drancourt M, Gouriet F, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 2009; 49:543-551.
12. van Veen SQ, Claas EC, Kuijper EJ. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. J Clin Microbiol 2010; 48:900-907.
13. Sauer S, Kliem M. Mass spectrometry tools for the classification and identification of bacteria. Nat Rev Microbiol 2010; 8:74-82.
14. La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. PLoS One 2009; 4:e8041.
15. Stevenson LG, Drake SK, Murray PR. Rapid identification of bacteria in positive blood culture broths by matrix-assisted laser desorption ionizationtime of flight mass spectrometry. J Clin Microbiol 2010; 48:444-447.
16. Ferreira L, Sanchez-Juanes F, Gonzalez-Avila M, et al. Direct identification of urinary tract pathogens from urine samples by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010; 48:2110-2115.
17. Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 2012. [Epub ahead of print].
18. Dekker J, Branda J. MALDI-TOF mass spectrometry in the clinical microbiology laboratory. Clin Microbiol Newsl 2011; 33:87-93.
19. Mardis ER. A decade's perspective on DNA sequencing technology. Nature 2011; 470:198-203.
20. Bode LG, van Wunnik P, Vaessen N, et al. Rapid detection of methicillinresistant Staphylococcus aureus in screening samples by relative quantification between the mecA gene and the SA442 gene. J Microbiol Methods 2012; 89:129-132.
21. Geiger K, Brown J. Rapid testing for methicillin-resistant Staphylococcus aureus: implications for antimicrobial stewardship. Am J Health Syst Pharm 2013; 70:335-342.
22. Peter H, Berggrav K, Thomas P, et al. Direct detection and genotyping of Klebsiella pneumoniae carbapenemases from urine by use of a new DNA microarray test. J Clin Microbiol 2012; 50:3990-3998.
23. Didelot X, Bowden R, Wilson DJ, et al. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 2012; 13:601-612.
24. Dunne WM Jr, Westblade LF, Ford B. Next-generation and whole-genome sequencing in the diagnostic clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis 2012; 31:1719-1726.
25. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
26. Bone RC. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA 1995; 273:155-156.
27. Kochanek K, Xu J, Murphy S, et al. Deaths: preliminary data for 2009. Centers for Disease Control. National Vital Statistics Reports 2011; 59.
28. Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754-761.
29. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goaldirected therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045-1053.
30. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003. (Pubitemid 43982479)
31. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217. (Pubitemid 46274517)
32. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011; 53:379-387.
33. Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012; 38:940-949.
34. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:426-435.
35. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-474.
36. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498-505. (Pubitemid 351442188)
37. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in 'real life': an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012; 172:715-722.
38. Liew YX, Lee W, Cai YY, et al. Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies. Eur J Clin Microbiol Infect Dis 2012; 31:3041-3046.
39. Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943-950.
40. Su L, Han B, Liu C, et al. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 2012; 12:157.
41. Gibot S, Bene MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186:65-71.
42. Ghafur A. The Chennai Declaration: a solution to the antimicrobial resistance problem in the Indian subcontinent. Clin Infect Dis 2013; 56:1190.
43. Davies S, Fowler T, Watson J, et al. Annual Report of the Chief Medical Officer infections and the rise of antimicrobial resistance 2011. Lancet 2013; 381:1606-1609.
44. Stockley JM. European Antibiotic Awareness Day 2012: getting smart about antibiotics, a public-professional partnership. J Infect 2012; 65:377-379.
45. Ashiru-Oredope D, Sharland M, Charani E, et al. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart-Then Focus. J Antimicrob Chemother 2012; 67 (Suppl 1):i51-i63.
46. Nathwani D, Sneddon J, Patton A, Malcolm W. Antimicrobial stewardship in Scotland: impact of a national programme. Antimicrob Resist Infect Control 2012; 1:7.
47. Kellie SM. Antimicrobial stewardship on the frontier: a pilot study of training using an electronic learning network. Infect Control Hosp Epidemiol 2012; 33:1181-1183.
48. Finch RG, Blasi FB, Verheij TJ, et al. GRACE and the development of an education and training curriculum. Clin Microbiol Infect 2012; 18:E308-E313.
49. Avo AB, Costa C, Amann G, et al. Implementation of the e-Bug Project in Portugal. J Antimicrob Chemother 2011; 66 (Suppl 5):v81-v83.
50. Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine 2012; 30:6509-6514.